Profile of serum bile acids in noncholestatic volunteers: Gender-related differences in response to fenofibrate

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 2, 2011, Pages 279-286

  Trottier, J ^a,b   Caron, P ^a,b   Straka, R J ^c   Barbier, O ^a,b  

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; DEOXYCHOLIC ACID; FENOFIBRATE; HYODEOXYCHOLIC ACID; LITHOCHOLIC ACID; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; CHOLESTASIS; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; BILE ACIDS AND SALTS; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PPAR ALPHA; SEX FACTORS;

EID: 79960608008     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.124     Document Type: Article

References (34)

1. Russell, D.W. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 50(suppl.), S120-S125 (2009).
2. Monte, M.J., Marin, J.J., Antelo, A. & Vazquez-Tato, J. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15, 804-816 (2009).
3. Araya, Z. & Wikvall, K. 6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochim. Biophys. Acta 1438, 47-54 (1999). (Pubitemid 29238516)
4. Bodin, K., Lindbom, U. & Diczfalusy, U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim. Biophys. Acta 1687, 84-93 (2005). (Pubitemid 40228988)
5. Pauli-Magnus, C. & Meier, P.J. Hepatocellular transporters and cholestasis. J. Clin. Gastroenterol. 39, S103-S110 (2005). (Pubitemid 40397023)
6. Wagner, M., Zollner, G. & Trauner, M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis. 30, 160-177 (2010).
7. Paumgartner, G. Pharmacotherapy of cholestatic liver diseases. J. Dig. Dis. 11, 119-125 (2010).
8. Barbier, O., Trottier, J., Kaeding, J., Caron, P. & Verreault, M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell. Biochem. 326, 3-8 (2009).
9. Brown, J.D. & Plutzky, J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115, 518-533 (2007). (Pubitemid 46184203)
10. Dohmen, K., Mizuta, T., Nakamuta, M., Shimohashi, N., Ishibashi, H. & Yamamoto, K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J. Gastroenterol. 10, 894-898 (2004). (Pubitemid 38418369)
11. Iwasaki, S., Akisawa, N., Saibara, T. & Onishi, S. Fibrate for treatment of primary biliary cirrhosis. Hepatol. Res. 37 (suppl. 3), S515-S517 (2007). (Pubitemid 47570668)
12. Iwasaki, S. et al.; Study Group of Intractable Liver Diseases for Research on a Specific Disease, Health Science Research Grant, Ministry of Health, Labour and Welfare of Japan. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol. Res. 38, 557-564 (2008). (Pubitemid 351622281)
13. Nakai, S., Masaki, T., Kurokohchi, K., Deguchi, A. & Nishioka, M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am. J. Gastroenterol. 95, 326-327 (2000). (Pubitemid 30041596)
14. Ohira, H., Sato, Y., Ueno, T. & Sata, M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 97, 2147-2149 (2002).
15. Barbier, O., Duran-Sandoval, D., Pineda-Torra, I., Kosykh, V., Fruchart, J.C. & Staels, B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDPglucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278, 32852-32860 (2003). (Pubitemid 37055727)
16. Hunt, M.C. et al. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J. Biol. Chem. 275, 28947-28953 (2000).
17. Li, T. & Chiang, J.Y. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009, 501739 (2009).
18. Gnewuch, C. et al. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J. Gastroenterol. 15, 3134-3141 (2009).
19. Scherer, M., Gnewuch, C., Schmitz, G. & Liebisch, G. Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 3920-3925 (2009).
20. Ye, L., Liu, S., Wang, M., Shao, Y. & Ding, M. High-performance liquid chromatography-tandem mass spectrometry for the analysis of bile acid profiles in serum of women with intrahepatic cholestasis of pregnancy. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 860, 10-17 (2007). (Pubitemid 350167544)
21. Xiang, X., Han, Y., Neuvonen, M., Laitila, J., Neuvonen, P.J. & Niemi, M. High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878, 51-60 (2010).
22. Tsai, M.Y. et al. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol. Genet. Metab. 100, 118-122 (2010).
23. Marrapodi, M. & Chiang, J.Y. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41, 514-520 (2000). (Pubitemid 30220654)
24. Fang, H.L., Strom, S.C., Cai, H., Falany, C.N., Kocarek, T.A. & Runge-Morris, M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 67, 1257-1267 (2005). (Pubitemid 40410426)
25. Yoon, M. et al. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp. Mol. Med. 34, 481-488 (2002). (Pubitemid 36114367)
26. Liu, Y. et al. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. J. Hum. Genet. 53, 709-717 (2008).
27. Hofmann, A.F. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev. 36, 703-722 (2004). (Pubitemid 39453070)
28. Sharma, R. et al. Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A). Bioorg. Med. Chem. 18, 6886-6895 (2010).
29. Levy, C. et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment. Pharmacol. Ther. 33, 235-242 (2011).
30. Chazouilles, O., Corpechot, C., Gaouar, F. & Poupon, R. Fenofibrate improves liver tests in primary sclerosing cholangitis with incomplete biochemical response to ursodeoxycholic acid. 61st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 29 October-2 November 2010, Hepatology, p. 488A.
31. Wojczynski, M.K. et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. J. Lipid Res. 51, 3316-3323 (2010).
32. Smith, J.A. et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur. J. Hum. Genet. 16, 603-613 (2008). (Pubitemid 351594127)
33. Lai, C.Q. et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler. Thromb. Vasc. Biol. 27, 1417-1425 (2007).
34. Shen, J. et al. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care 31, 910-915 (2008).